{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:32:41Z","timestamp":1758637961206,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T00:00:00Z","timestamp":1554768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00228-019-02675-4","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T11:03:15Z","timestamp":1554807795000},"page":"1109-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Endres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Ridders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,9]]},"reference":[{"issue":"4","key":"2675_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00406-016-0736-z","volume":"267","author":"M Paulzen","year":"2017","unstructured":"Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Grunder G, Schoretsanitis G (2017) Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci 267(4):325\u2013333. \n                    https:\/\/doi.org\/10.1007\/s00406-016-0736-z","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2675_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","volume":"73","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Haen E, Stegmann B, Hiemke C, Gr\u00fcnder G, Lammertz SE, Schoretsanitis G (2016) Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; a pharmacokinetics-based hypothesis. Psychoneuroendocrinology 73:9\u201315. \n                    https:\/\/doi.org\/10.1016\/j.psyneuen.2016.07.009","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"2675_CR3","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/bcp.13255","volume":"83","author":"M Paulzen","year":"2017","unstructured":"Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz SE, Gr\u00fcnder G, Schoretsanitis G (2017) Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol 83(8):1668\u20131675. \n                    https:\/\/doi.org\/10.1111\/bcp.13255","journal-title":"Br J Clin Pharmacol"},{"key":"2675_CR4","doi-asserted-by":"crossref","unstructured":"Paulzen M, Haen E, Gr\u00fcnder G, Stegmann B, Schruers KJR, Walther S, Lammertz SE, Schoretsanitis G (2016) Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol 30(8):803\u2013809","DOI":"10.1177\/0269881116650390"},{"issue":"9","key":"2675_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-016-2085-2","volume":"72","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Stegmann B, Hiemke C, Gr\u00fcnder G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M (2016) Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 72(9):1091\u20131098. \n                    https:\/\/doi.org\/10.1007\/s00228-016-2085-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"9665","key":"2675_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","volume":"373","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373(9665):746\u2013758. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(09)60046-5","journal-title":"Lancet"},{"issue":"5","key":"2675_CR7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","volume":"20","author":"SM Fogelman","year":"1999","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20(5):480\u2013490. \n                    https:\/\/doi.org\/10.1016\/S0893-133X(98)00113-4","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"2675_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","volume":"32","author":"KJ Klamerus","year":"1992","unstructured":"Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST (1992) Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 32(8):716\u2013724","journal-title":"J Clin Pharmacol"},{"key":"2675_CR9","doi-asserted-by":"crossref","unstructured":"Kuzin M, Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gr\u00fcnder G, Paulzen M (2017) Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450 mediated metabolism of venlafaxine. Clin Pharmacokinet in press","DOI":"10.1007\/s40262-017-0591-8"},{"issue":"1\u201302","key":"2675_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(1\u201302):9\u201362. \n                    https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"issue":"4\u20135","key":"2675_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-0034-1383565","volume":"47","author":"TJ Stamm","year":"2014","unstructured":"Stamm TJ, Becker D, Sondergeld LM, Wiethoff K, Hiemke C, O'Malley G, Ricken R, Bauer M, Adli M (2014) Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. Pharmacopsychiatry 47(4\u20135):174\u2013179. \n                    https:\/\/doi.org\/10.1055\/s-0034-1383565","journal-title":"Pharmacopsychiatry"},{"issue":"1\u20133","key":"2675_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.schres.2015.10.021","volume":"169","author":"NE Steen","year":"2015","unstructured":"Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, Gardsjord E, Morch R, Agartz I, Melle I, Vaskinn A, Spigset O, Andreassen OA (2015) Serum level of venlafaxine is associated with better memory in psychotic disorders. Schizophr Res 169(1\u20133):386\u2013392. \n                    https:\/\/doi.org\/10.1016\/j.schres.2015.10.021","journal-title":"Schizophr Res"},{"issue":"6","key":"2675_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0032-1326769","volume":"45","author":"S Unterecker","year":"2012","unstructured":"Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, Pfuhlmann B (2012) The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry 45(6):229\u2013235. \n                    https:\/\/doi.org\/10.1055\/s-0031-1301366","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"2675_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00007691-200004000-00011","volume":"22","author":"AH Veefkind","year":"2000","unstructured":"Veefkind AH, Haffmans PM, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22(2):202\u2013208","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2675_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1055\/s-0042-105443","volume":"49","author":"E Berm","year":"2016","unstructured":"Berm E, Kok R, Hak E, Wilffert B (2016) Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry. Pharmacopsychiatry 49(5):186\u2013190. \n                    https:\/\/doi.org\/10.1055\/s-0042-105443","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"2675_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/026988110201600413","volume":"16","author":"C Charlier","year":"2002","unstructured":"Charlier C, Pinto E, Ansseau M, Plomteux G (2002) Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol 16(4):369\u2013372. \n                    https:\/\/doi.org\/10.1177\/026988110201600413","journal-title":"J Psychopharmacol"},{"issue":"11","key":"2675_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00213-014-3825-6","volume":"232","author":"F Jiang","year":"2015","unstructured":"Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW (2015) The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology 232(11):1899\u20131909. \n                    https:\/\/doi.org\/10.1007\/s00213-014-3825-6","journal-title":"Psychopharmacology"},{"issue":"11","key":"2675_CR18","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.4088\/JCP.08m04773blu","volume":"71","author":"KW Lobello","year":"2010","unstructured":"Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT (2010) Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 71(11):1482\u20131487. \n                    https:\/\/doi.org\/10.4088\/JCP.08m04773blu","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2675_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/01.pra.0000445247.54048.68","volume":"20","author":"SH Preskorn","year":"2014","unstructured":"Preskorn SH (2014) Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don't work. J Psychiatr Pract 20(2):133\u2013137. \n                    https:\/\/doi.org\/10.1097\/01.pra.0000445247.54048.68","journal-title":"J Psychiatr Pract"},{"issue":"6","key":"2675_CR20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/YIC.0000000000000234","volume":"33","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Haen E, Hiemke C, Fay B, Unholzer S, Correll CU, Grunder G, Paulzen M (2018) Sex and body weight are major determinants of venlafaxine pharmacokinetics. Int Clin Psychopharmacol 33(6):322\u2013329. \n                    https:\/\/doi.org\/10.1097\/YIC.0000000000000234","journal-title":"Int Clin Psychopharmacol"},{"issue":"05","key":"2675_CR21","first-page":"A23","volume":"41","author":"A K\u00f6stlbacher","year":"2008","unstructured":"K\u00f6stlbacher A, Haen E (2008) Konbest\u2013a web-based laboratory information management system (LIMS) for TDM-laboratories. Pharmacopsychiatry 41(05):A23","journal-title":"Pharmacopsychiatry"},{"key":"2675_CR22","doi-asserted-by":"crossref","unstructured":"Guy W (1976) ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Publ No ADM 76-338 National Institute of Mental Health, Rockville","DOI":"10.1037\/e591322011-001"},{"key":"2675_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.psychres.2016.04.034","volume":"240","author":"V Carlo De","year":"2016","unstructured":"De Carlo V, Calati R, Serretti A (2016) Socio-demographic and clinical predictors of non-response\/non-remission in treatment resistant depressed patients: a systematic review. Psychiatry Res 240:421\u2013430. \n                    https:\/\/doi.org\/10.1016\/j.psychres.2016.04.034","journal-title":"Psychiatry Res"},{"key":"2675_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jad.2015.09.033","volume":"189","author":"M Balestri","year":"2016","unstructured":"Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A (2016) Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord 189:224\u2013232. \n                    https:\/\/doi.org\/10.1016\/j.jad.2015.09.033","journal-title":"J Affect Disord"},{"issue":"5726","key":"2675_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/bmj.4.5726.18","volume":"4","author":"M Asberg","year":"1970","unstructured":"Asberg M, Cronholm B, Sjoqvist F, Tuck D (1970) Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 4(5726):18\u201321","journal-title":"Br Med J"},{"issue":"4","key":"2675_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-2006-946701","volume":"39","author":"M Hendset","year":"2006","unstructured":"Hendset M, Haslemo T, Rudberg I, Refsum H, Molden E (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 39(4):121\u2013127. \n                    https:\/\/doi.org\/10.1055\/s-2006-946701","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"2675_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuron.2007.11.017","volume":"57","author":"M Uhr","year":"2008","unstructured":"Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F (2008) Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57(2):203\u2013209. \n                    https:\/\/doi.org\/10.1016\/j.neuron.2007.11.017","journal-title":"Neuron"},{"issue":"9","key":"2675_CR28","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/archgenpsychiatry.2009.95","volume":"66","author":"M Ising","year":"2009","unstructured":"Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Muller-Myhsok B (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66(9):966\u2013975. \n                    https:\/\/doi.org\/10.1001\/archgenpsychiatry.2009.95","journal-title":"Arch Gen Psychiatry"},{"key":"2675_CR29","doi-asserted-by":"publisher","unstructured":"Arakawa R, Stenkrona P, Takano A, Svensson J, Andersson M, Nag S, Asami Y, Hirano Y, Halldin C, Lundberg J (2019) Venlafaxine ER blocks the norepinephrine transporter in the brain of patients with major depressive disorder: a PET study using [18F]FMeNER-D2. Int J Neuropsychopharmacol. \n                    https:\/\/doi.org\/10.1093\/ijnp\/pyz003","DOI":"10.1093\/ijnp\/pyz003"},{"issue":"2","key":"2675_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","volume":"59","author":"J Leon de","year":"2009","unstructured":"de Leon J (2009) The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 59(2):81\u201389. \n                    https:\/\/doi.org\/10.1016\/j.phrs.2008.10.002","journal-title":"Pharmacol Res"},{"issue":"4","key":"2675_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/00007691-200208000-00014","volume":"24","author":"M Reis","year":"2002","unstructured":"Reis M, Lundmark J, Bjork H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24(4):545\u2013553","journal-title":"Ther Drug Monit"},{"issue":"2","key":"2675_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00213-010-2148-5","volume":"215","author":"L Karlsson","year":"2011","unstructured":"Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, Schmitt U, Kugelberg FC (2011) Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology 215(2):367\u2013377. \n                    https:\/\/doi.org\/10.1007\/s00213-010-2148-5","journal-title":"Psychopharmacology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02675-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02675-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T23:05:12Z","timestamp":1586300712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02675-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,9]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2675"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02675-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2019,4,9]]},"assertion":[{"value":"30 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ekkehard Haen received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE, a non-profit working group to improve drug safety and efficacy in the treatment of psychiatric diseases. He reports no conflict of interest with this publication. Gerhard Gr\u00fcnder has served as a consultant for Boehringer Ingelheim (Ingelheim, Germany), Cheplapharm (Greifswald, Germany), Eli Lilly (Indianapolis, Ind, USA), Lundbeck (Copenhagen, Denmark), Ono Pharmaceuticals (Osaka, Japan), Roche (Basel, Switzerland), Servier (Paris, France), and Takeda (Osaka, Japan). He has served on the speakers\u2019 bureau of Eli Lilly, Gedeon Richter (Budapest, Ungarn), Janssen Cilag (Neuss, Germany), Lundbeck, Roche, Servier, and Trommsdorf (Aachen, Germany). He has received grant support from Boehringer Ingelheim and Roche. He is co-founder of Pharma Image GmbH (D\u00fcsseldorf, Germany) and Brainfoods UG (Selfkant, Germany). He reports no conflict of interest with this publication. Christoph Hiemke has received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Astra Zeneca, Janssen-Cilag, Pfizer, Lilly, and Servier. He is managing director of the psiac GmbH which provides an Internet-based drug\u2013drug interaction program for psychopharmacotherapy. He reports no conflict of interest with this publication. Christoph Correll has been a consultant and\/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen\/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, ROVI, Servier, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. All other authors declare no conflicts of interest as well. The research study did not receive funds or support from any source.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No informed consent was necessary for this type of research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}